Tau protein kinases: Involvement in Alzheimer's disease

Martin, Ludovic, Latypova, Xenia, Wilson, Cornelia M., Magnaudeix, Amandine, Perrin, Marie-Laure, Yardin, Catherine, Terro, Faraj·2013·Ageing Research Reviews
DOI 10.1016/j.arr.2012.06.003

Cited by (646)

Items 601–646 of 646

  1. MUSASHI1 promotes tau phosphorylation by activating the p38 MAPK pathway
    Wenshuang Li, Baomiao Ma, Xiang Tian, Qi Xiong, Mengqi Zhou, Wei Da Liu, Xiji Shu · 2025 · Neurochemistry International
  2. Revisiting COX-2 inhibitors for Alzheimer's disease as multitargeted ligands: Development of 4-hydrazono-pyrazolidinediones with tuned COX selectivity profile and improved cellular potency
    Reham Waheed, Zeinab Mostafa, Maryam Emad, Sarah S. Darwish, Rosa Purgatorio, Daniela Valeria Miniero, Annalisa De Palma, Tzu‐Peng Cheng, Tingyu Wang, Yu‐Cheng Chen et al. · 2025 · European Journal of Medicinal Chemistry
  3. Additional file 1 of Functional insights from targeted imaging BACE1: the first near-infrared fluorescent probe for Alzheimer’s disease diagnosis
    Anyao Bi, Wu, Junyong, Huang, Shuai, Li, Yongjiang, Fan Zheng, Ding, Jipeng, Dong, Jie, 向大雄, Zeng, Wenbin · 2023 · Figshare
  4. Étude de l’agrégation des protéines intrinsèquement désordonnées impliquées dans les maladies d’Alzheimer et de Parkinson
    Juan M. Lopez · 2015 · theses.fr (ABES)
  5. Rôle des modifications post-traductionnelles dans le processus d’agrégation de la protéine Tau
    Clément Despres · 2017 · theses.fr (ABES)
  6. NMR study of 14-3-3 protein-protein interactions and modulation thereof by small molecules
    João Filipe Neves · 2019
  7. Implication of 3S-HS and HS3ST2 in synaptic stability under physiological conditions and in Alzheimer's disease-related tauopahty
    Auriane Maïza · 2019 · theses.fr (ABES)
  8. Rôle central des glucocorticoïdes et de leurs récepteurs dans l’étiologie de la Maladie d’Alzheimer
    Geoffrey Canet · 2020 · theses.fr (ABES)
  9. Novel FUS and CHCHD10 models to investigate pathogenic mechanisms in Amyotrophic Lateral Sclerosis
    Annis-Rayan Bourefis · 2019 · theses.fr (ABES)
  10. Potentialisation des effets de composés phénoliques combinés de l’huile d’olive : étude des transformations rédox : application dans les maladies neurodégénératives
    Morgane Lambert de Malezieu · 2019 · theses.fr (ABES)
  11. Study of 3-O-sulfated heparan sulfates on tauopathy development in AD : neuropathologic and cellular approach
    Nicolas Rebergue · 2022 · theses.fr (ABES)
  12. Design, synthesis and characterization of protein-protein interaction disruptors related to early amyloidogenic phenomena in Alzheimer's disease
    Johanna Giovannini · 2021 · theses.fr (ABES)
  13. Caractérisation des mécanismes moléculaires impliqués dans la mise en place des altérations cérébrales dans un modèle préclinique de diabète de type 2
    Rim Hamzé · 2023 · theses.fr (ABES)
  14. Role of T-cell immunity in the pathophysiology of Alzheimer’s disease and other Tauopathies
    Karen Matta · 2024 · theses.fr (ABES)
  15. Transforming MRI Data Into Latent Space Embeddings Using Multi-Head Learning to Understand Alzheimer's Progression
    Manasvini Singh · 2026 · International Conference on Visual Analytics and Data Visualization (ICVADV)
  16. Machine Learning-Driven Ensemble Screening of Multitarget Kinase Inhibitors for Tauopathy-Associated Neurodegeneration Using All-Atom and Steered MD Simulations
    Arunabh Choudhury, Mohammad Umar Saeed, Sneh Prabha, Md. Imtaiyaz Hassan · 2026 · ACS Chemical Neuroscience
  17. Calorimetric, Thermogravimetric, and Theoretical Study of Norharmane, Harmane, and Harmine: Insights into the Energetics of β-Carbolines
    Ana I. Delgado-Moreno, Raúl R. Quiñonez-López, María de Jesús Palacios-Sánchez, Oscar Guillermo Zúñiga-González, Francisco Javier Moscoso‐Sánchez, Eulogio Orozco‐Guareño, Jesús Baudelio Campos-García · 2026 · Thermo
  18. The emerging role of polo-like kinase 2 in Alzheimer's disease
    Laura Martínez-Drudis, Razan Sheta, Dylan Musiol, Maxime Teixeira, Abid Oueslati · 2026 · Experimental Neurology
  19. Protein Modifications and Quality Control System: Target for Alzheimer’s Disease Therapy
    Abdullah Md. Sheikh, Shozo Yano, Shatera Tabassum, Jubo Bhuiya, Atsushi Nagai · 2026 · International Journal of Molecular Sciences
  20. Neuronal PRRT3 coordinates amyloidogenic processing and Tau phosphorylation via distinct Ras-ERK-AP-1 and CaMKII/PP2A pathways
    Fei Chen, Haohan Zhang, Yaru Huang, Jie Zhu, Fang Cui, Shiyu Liang, Yangjie Li, Yujiong Wang, Xixiu Xie, Ruitian Liu · 2026 · Acta Biochimica et Biophysica Sinica
  21. Protein kinase C in neurodegenerative disorders
    Azadeh Hekmat, Ali Akbar Saboury · 2026 · Elsevier eBooks
  22. Nanotechnology-based Therapeutic Approach in Alzheimer's Disease
    Rajdip Goswami, Priyanka Banerjee, Saptarshi Sanyal, Biswajit Basu, Monosiz Rahaman · 2026 · BENTHAM SCIENCE PUBLISHERS eBooks
  23. Tau Protein in Alzheimer's Disease
    Maitreyee Mukherjee, Soumen Dhara, Abhishek Jana, Tathagata Roy · 2026 · BENTHAM SCIENCE PUBLISHERS eBooks
  24. Neuroprotective or Destructive? A Comprehensive Review on Plant Peptides for Neurodegenerative Disease
    Pulak Majumder, Trisita Majumder · 2026 · Peptide Science
  25. Establishment of Serum Cholesterol Sulfate Reference Intervals and Evaluation of Its Diagnostic and Metabolic Associations in Chinese Adults
    Yin Liu, Xucong Ji, Xiaoqian Yu, Hongmei Zhang, Xinhua Dai, Zhiguang Su · 2026 · Diagnostics
  26. Catestatin peptide ameliorates tauopathy and amyloidogenesis via adrenergic inhibition
    Suborno Jati, Satadeepa Kal, Daniel Muñoz-Mayorga, Kechun Tang, Debashis Sahoo, Xu Chen, Sushil K. Mahata · 2026 · Molecular Therapy
  27. Restoration of Normal Occlusion Suppresses the Risk of Dementia
    Munehisa Maeshiba, Hiroshi Kajiya, Keisuke Migita, Kazuko Goto-T, Takayoshi Seki, Takashi Tsuzuki · 2026 · Neurochemical Research
  28. Monoallelic variants in BRSK1 are associated with a neurodevelopmental disorder with or without epilepsy
    Mingxi Deng, Mengqi Ma, Vanessa Andrea Gomez, Jinghan Zhao, Shenzhao Lu, Shabab B. Hannan, Stephanie Baskin, Amjad Khan, Donald R. Latner, Susan M. Hiatt et al. · 2026 · The American Journal of Human Genetics
  29. BindingDB Entry 50045607: Synthesis and molecular modelling studies of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors.
    BindingDB · 2016 · UC San Diego
  30. BindingDB Entry 50018506: β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.
    BindingDB · 2024 · UC San Diego
  31. BindingDB Entry 50048229: MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation.
    BindingDB · 2018 · UC San Diego
  32. BindingDB Entry 50043631: 2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3ß inhibitors.
    BindingDB · 2014 · UC San Diego
  33. BindingDB Entry 50022831: A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD).
    BindingDB · 2026 · UC San Diego
  34. BindingDB Entry 50012598: An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.
    BindingDB · 2022 · UC San Diego
  35. data files for Sadleir et al, "Annexin A6 membrane repair protein protects against amyloid-induced dystrophic neurites and tau phosphorylation in Alzheimer's disease model mice," 2025, Acta Neuropathologica
    Katherine R. Sadleir · 2025 · Galter Health Sciences Library, Northwestern University
  36. BindingDB Entry 50045479: Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3ß inhibitors for Alzheimer's disease.
    BindingDB · 2016 · UC San Diego
  37. BindingDB Entry 50048224: Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.
    BindingDB · 2018 · UC San Diego
  38. BindingDB Entry 50043969: Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.
    BindingDB · 2014 · UC San Diego
  39. BindingDB Entry 7414: Synthesis of pyrimidin-4-one-1,2,3-triazole conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity.
    BindingDB · 2016 · UC San Diego
  40. BindingDB Entry 50010235: Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.
    BindingDB · 2021 · UC San Diego
  41. BindingDB Entry 50016393: Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.
    BindingDB · 2023 · UC San Diego
  42. BindingDB Entry 50001103: Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.
    BindingDB · 2020 · UC San Diego
  43. BindingDB Entry 50017568: ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.
    BindingDB · 2023 · UC San Diego
  44. BindingDB Entry 50008884: Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3.
    BindingDB · 2021 · UC San Diego
  45. BindingDB Entry 50002303: Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents.
    BindingDB · 2020 · UC San Diego
  46. BindingDB Entry 50042364: Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases.
    BindingDB · 2013 · UC San Diego